Browsing Leishmaniasis/Kala Azar by Authors
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized TrialWasunna, M; Njenga, S; Balasegaram, M; Alexander, N; Omollo, R; Edwards, T; Dorlo, TPC; Musa, B; Ali, MHS; Elamin, MY; et al. (Public Library of Science (PLoS), 2016-09-14)SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa.
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, IndiaGoyal, Vi; Mahajan, R; Pandey, K; Singh, SN; Singh, RS; Strub-Wourgaft, N; Alves, F; Rabi Das, VN; Topno, RK; Sharma, B; et al. (Public Library of Science, 2018-10-22)In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown excellent results, there remains a lack of evidence on a wider treatment population and the safety and effectiveness of these regimens under field conditions.
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance ProgrammeKimutai, R; Musa, AM; Njoroge, S; Omollo, R; Alves, F; Hailu, A; Khalil, EAG; Diro, E; Soipei, P; Musa, B; et al. (Springer Link, 2017-01-09)In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed.